Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia.
Anders GranholmMaj-Brit Nørregaard KjærMarie Warrer MunchSheila Nainan MyatraBharath Kumar Tirupakuzhi VijayaraghavanMaria CronhjortRebecka Rubenson WahlinStephan M JakobLuca CioccariGitte Kingo VesterlundTine Sylvest MeyhoffMarie HellebergMorten Hylander MøllerThomas BenfieldBalasubramanian VenkateshNaomi E HammondSharon MicallefAbhinav BassiOommen JohnVivekanand JhaKlaus Tjelle KristiansenCharlotte Suppli UlrikVibeke Lind JørgensenMargit SmittMorten H BestleAnne Sofie AndreasenLone Musaeus PoulsenBodil Steen RasmussenAnne Craveiro BrøchnerThomas StrømAnders MøllerMohd Saif KhanAjay PadmanabanJigeeshu Vasishtha DivatiaSanjith SaseedharanKapil BorawakeFarhad KapadiaSubhal DixitRajesh ChawlaUrvi ShuklaPravin AminMichelle S ChewChristian Aage WambergNeeta BoseMehul S ShahIben S DarfeltChristian GluudTheis LangeAnders PernerPublished in: Intensive care medicine (2022)
Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose.